BiotechTube
Adragos Pharma

Adragos Pharma

Munich, Germany· Est.
adragos-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

Adragos Pharma is a Germany-based, global CDMO founded in 2018, offering integrated pharmaceutical development and manufacturing services. It has rapidly built a strategic network of seven specialized facilities across Europe and Japan, providing capabilities in sterile/non-sterile liquids, solids, semi-solids, biologics, orphan drugs, and advanced technologies like Blow-Fill-Seal and lyophilization. The company is led by an experienced management team with deep pharmaceutical industry expertise and serves a global clientele in pharma and biotech, positioning itself as a one-stop partner for streamlining drug product supply chains.

Drug DeliverySmall Molecules

Technology Platform

Integrated network of specialized pharmaceutical manufacturing technologies including sterile Blow-Fill-Seal (BFS), aseptic fill-finish, lyophilization, HPAPI containment, and production of solids, semi-solids, and non-sterile liquids.

Funding History

3
Total raised:$105M
Series B$50M
Series A$30M
Series A$25M

Opportunities

The company is well-positioned to capitalize on the strong outsourcing trend in pharma, the growth of complex biologics and potent compounds (HPAPIs), and the demand for regionalized supply chains.
Its unique integrated network model allows it to offer end-to-end services from a single partner, a key advantage for biotechs seeking to de-risk development.

Risk Factors

Key risks include operational and quality failures at any of its global sites, high competition in the CDMO sector, dependence on the biotech funding environment, and the challenges of integrating a multi-national network of acquired facilities into a cohesive, high-performing organization.

Competitive Landscape

Adragos competes in a fragmented but competitive global CDMO market against large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as numerous specialized and regional CDMOs. Its differentiation lies in its integrated multi-technology European network with a strategic site in Japan, offering a broad service portfolio from a mid-sized, potentially more agile partner.

More companies in Biologics / Biosimilars →More companies in Germany →